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ttp://dx.doi.org/10.1016/j.ajpath.2014.01.008Cancer treatment continues to be challenged by the development of therapeutic resistances and re-
lapses in the clinical setting, which are largely attributed to tumor heterogeneity, particularly the
existence of cancer stem cells (CSCs). Thus, targeting the CSC subpopulation may represent an effective
therapeutic strategy. However, despite advances in identifying and characterizing CD133þ CSCs in
various human cancers, efforts to translate these experimental ﬁndings to clinical modalities have been
slow in the making, especially in light of the growing awareness of CSC plasticity and the foreseeable
pitfall of therapeutically targeting CSC base sorely on a surface marker. We, and others, have demon-
strated that the CD133þ CSCs reside in complex vascular niches, where reciprocal signaling between the
CD133þ CSCs and their microenvironment may govern niche morphogenesis and homeostasis. Herein,
we discuss the multifaceted functional role of the CD133þ cells in the context of their niche, and the
potential of targeting CD133 as a niche-dependent approach in effective therapy. (Am J Pathol 2014,
184: 1256e1262; http://dx.doi.org/10.1016/j.ajpath.2014.01.008)Supported in part by National Cancer Institute, NIH, grant R01
CA138649 (M.-Y.H.); the Department of Pathology, Brigham and
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(M.-Y.H.); and a Mach-Gaensslen Foundation of Canada grant (A.B.M.).
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Disclosures: None declared.Solid tumors and hematopoietic cancers are morphologi-
cally and functionally heterogeneous, which is believed to
be attributed to subpopulations of tumor cells with stem
cellelike properties, termed cancer stem cells (CSCs). Such
as their normal stem cell counterparts, CSCs are primitive
cell entities able to self-renew and asymmetrically divide to
maintain a stem cell pool, as well as differentiated cell
progenies.1 On the basis of these criteria, CSCs have been
isolated or enriched from numerous tissue types and
demonstrated to exhibit increased resistance to conventional
cancer treatments, including chemotherapy and radio-
therapy, which can be partially explained by their quies-
cence, up-regulation of efﬂux transporters, and increased
ability for DNA damage repair.1 Taken together, CSCs may
explain cancer relapses and metastases, which have led tostigative Pathology.
.the argument that targeting CSCs may yield improved sur-
vival and treatment outcomes for patients.
The identiﬁcation and characterization of CSCs is largely
owed to the use of cell-surface markers. Although this
approach has been widely applied for a range of solid tumors
and hematopoietic cancers from varying tissue types, there is
evidence that the CSC phenotype may be acquired or induced
in cancer cells lacking CSC markers, such as glioma or
Figure 1 The complex vascular niche of CD133þ CSCs in melanoma.
CD133þ CSCs reside in a complex anastomosing microvascular niche encom-
passing CSC-lined VM channels, mosaic vessels, and authentic blood vessels
lined by bona ﬁde ECs. CSCs may contribute to niche morphogenesis through
vascular endothelial growth factor (VEGF) secretion, which then induces
multiple pathways for niche vascularization, including vasculogenic mimicry
(1), direct transdifferentiation of CD133þ CSCs to CD31þ tumor-derived
endothelium (2), and recruitment of ECs (3) and EPCs (4) for angiogenesis.
Targeting CD133 in Cancer Treatmentpancreatic cancer cells.2,3 These observations challenge the
hierarchical CSC hypothesis and propose a stochastic model,
whereby non-CSCs can acquire stem cell properties through
mutations or external cues.2 Thus, stem cell properties of
tumor cells are dynamic, and strategies that solely target
CSCs may not be effective because CSCs may be replenished
through phenotypic switching from non-CSCs.
CD133 is an approximately 120-kDa pentaspan trans-
membrane glycoprotein that is primarily localized to the
plasma membrane, and its cell-surface epitope, AC133, has
been highly used as a cell-surface marker to isolate and
enrich for CSCs from a wide range of tissue types.4
Consistent with its role as a CSC marker, CD133 expres-
sion has been associated with increased chemoresistance
and radioresistance, as well as a poor prognosis in various
cancers.4,5 However, its utility as a CSC marker has been
the subject of controversy because CD133 has been
demonstrated to be expressed in differentiated cell pop-
ulations,4 and the CD133e fractions have been shown to
initiate tumor in vivo.6,7 We, and others, have partially
addressed this concern by demonstrating that the AC133
epitope is regulated by speciﬁc CD133 N-glycosylation
processing,8,9 as well as alternative splicing.10 Indeed, cell-
surface AC133 appears to be speciﬁc to stem cell pop-
ulations and is lost during differentiation, whereas CD133
protein and mRNA expression can be maintained.8
Furthermore, the tumorigenic property of CD133 tumor
subsets is believed to arise in cancer cells that either harbor
masked CD133 epitopes11 or subsequently induced CD133
because of environmental cues.2,3 Compelling evidence
suggests that certain CD133 glycoforms not only serve as a
marker for CSCs, but also contribute to cell survival,
maintenance of stemness, and tumorigenesis.12e14 In addi-
tion, recent ﬁndings have linked CD133 to tumor vascu-
larization, because it appears to be required not only for
angiogenesis, such as in brain tumors,15 but also vasculo-
genic mimicry (VM) in melanoma,12 beast,16 and brain17
cancers. Despite these advances, the functions of CD133
in various cancer types at the cellular and molecular levels
remain an underdeveloped area of research. In this review,
we will discuss the known and hypothesized roles of
CD133-expressing subsets in the vascular niche and their
potential as targets for niche-dependent therapy.
Vascular Niche of CD133D CSCs
Signiﬁcance of VM
Like normal stem cells, CSCs exist in specialized compart-
ments within the tumor known as niches. Such niches pro-
vide the essential cues for cell fate determination, by
achieving a balance between self-renewal and differentiation.
For example, Calabrese et al18 demonstrated that the
CD133þ brain cancer stem cells are localized to the peri-
vascular microenvironment, the so-called perivascular niche.
Disruption of such perivascular niches ablates the CD133þThe American Journal of Pathology - ajp.amjpathol.orgbrain tumor stem/initiating cells, resulting in growth arrest.18
Correspondingly, similar vascular niches of CD133þ CSCs
have also recently been identiﬁed in melanoma, albeit in a
more complex context of tumor microcirculation.12
The VM, originally described in uveal melanoma,19 con-
notes the PAS-positive, patterned networks and channels lined
externally by CD31 tumor cells with endothelial phenotypes,
such as CD144 (vascular endothelial cadherin), Tie-1, and
EphA2 expression.20e22 The documentation of intraluminal
blood cells within the VM channels and mosaic vessels
partially lined by VM-engaging tumor cells and bona ﬁde
CD31þ endothelial cells and the reported up-regulation of
genes involved in anti-coagulation mechanisms in VM-
engaging tumor cells have provided evidence for the perfus-
ability of VM networks.22 Therefore, VM networks constitute
an alternative mechanism for nutrient supply and act as a po-
tential access point for metastases.5 To date, VM has been
observed in a broad range of cancer types, including, but not
limited to, melanoma, glioblastoma, astrocytoma, various car-
cinomas, and sarcoma,23e27 and is associated with increased
tumor aggressiveness23 and patient mortality.28 Expression
gene proﬁling using microarray analyses reveals that VM-
engaging melanoma cells exhibit a pluripotent, primitive
phenotype, co-expressing multiple lineage-speciﬁc genes,
including those of endothelial, epithelial, ﬁbroblastic, he-
matopoietic, renal, neuronal, muscular, and precursor/progen-
itor cell types.29 These ﬁndings suggest that the VM-engaging1257
Mak et almelanoma cells possess stem cellelike properties with
phenotypic plasticity to serve endothelial function. We previ-
ously reported that the CD133þ melanoma CSC subsets
coincide with the areas of VM in a complex anastomosing
microvascular niche, encompassing CD144þ melanoma-lined
VM channels, mosaic vessels, and authentic endothelial
cellelined blood vessels (Figure 1).12 Double immunoﬂuo-
rescence reveals that the spatial arrangement of putative
marker-positive melanoma CSC subsets within the vascular
niche is not random. In most cases, there appears to be com-
plete overlap between the perivascular CD133þ and CD144þ
subsets (Figure 2A). At times, the CD133þ subset partially
overlaps with the CD144þ fraction, with the latter exhibiting a
more restricted perivascular pattern (Figure 2, B and C). On the
rare occasion, a mutually exclusive zonal pattern, in which the
CD144þ VM-engaging subset closely approximates the
CD31þ endothelium-lined blood vessels with abrupt transition
to the CD133þ subpopulation radially, is observed (Figure 2D).Figure 2 Colocalization of CD133þ CSCs and CD144þ vasculogenic
mimicry-engaging tumor subsets to vascular niche in melanoma xenografts.
Double-immunoﬂuorescence staining in consecutive sections (left and
right panels) demonstrates different spatial arrangements of the CD133þ
and CD144þ CSC subsets within vascular niches of WM1617 melanoma
xenografts [anti-CD31 (red) decorates endothelium (EC)-lined blood ves-
sels]: A: Complete overlap of perivascular CD133þ (left panel, green) and
CD144þ (right panel, green) subpopulations. B and C: Partial overlap of
the CD144þ population (right panel, green) with a subset of CD133þ cells
(left panel, green) perivascularly. D: Mutually exclusive zonal arrangement
with the CD144þ population (right panel, green) intimately associated
with CD31þ endothelium-lined blood vessels, which abruptly transits to the
CD133þ population peripherally (left panel, green).
1258These ﬁndings suggest a zonal gradient of microenvironmental
cues within the vascular niche in controlling the CSC pheno-
type. Deciphering the molecular signals in the vascular niche
that governs CSC phenotype presents a golden opportunity for
novel therapeutic targets taking advantage of the codependence
between CSCs and their niches.
CD133þ CSC Subsets Contribute to VM
Interestingly, CD133þ CSCs have been shown to induce
VM channels in triple-negative breast cancer16 and glio-
blastoma,17 characterized by their enrichment of CD144 and
downstream up-regulation of the matrix metalloproteinases
2 (MMP-2) and 9 (MMP-9), which cleave the extracellular
matrix (ECM), laminin 5 subunit g2 (LAMC2).5 Consis-
tently, we found that down-regulating CD133 with RNA
interference resulted in decreased VM formation in mela-
noma xenografts.12 Although the molecular mechanism
underlying VM modulation by CD133 is presently un-
known, we have recently demonstrated that CD133 up-
regulates LAMC2 transcriptional expression via b-catenin
signaling in colorectal and ovarian carcinoma cell lines,30
suggesting that CD133 contributes to VM induction by
regulating the ECM (Figure 3). The observations that
LAMC2, MMP-2, and MMP-9 colocalize to VM channels
and that ECM deposited by VM-forming tumor cells in-
duces VM in nonaggressive melanoma cells, and even
normal melanocytes,31 further support the hypothesis that
VM-engaging CSCs may modulate the local ECM compo-
sition to promote VM32 and, thereby, perivascular niche
morphogenesis. Indeed, targeting the ECM component,
LAMC2, in melanoma resulted in inhibition of VM initia-
tion.32,33 In addition, CD133þ glioblastoma stem cells that
underwent VM formations display increased expression of
vascular endothelial growth factor (VEGF) and other pro-
angiogenic factors,34 and VEGF knockdown in osteosar-
coma abolishes VM.35 VEGF may regulate VM formation
via an autocrine signaling, because Adini et al15 recently
showed that CD133 interacts with VEGF and potentiates its
action in both melanoma and vascular endothelial cells
(Figure 3). Taken together, CD133þ fractions contribute to
VM through multiple mechanisms, including modulating
pro-VM ECM and up-regulating and potentiating VEGF
(Figure 3).
Perivascular Niche and Maintenance of the CSC
Phenotype
In addition to inducing VM, ample evidence suggests that
VM/niche-associated ECM may also regulate stemness.
For example, galectin-3, a member of the lectin family,
positively regulates CD144 expression and its downstream
effector molecule, MMP-2, in melanoma (Figure 3).36
Consistently, silencing galectin-3 expression prevented
VM formation and invasion of an aggressive cutaneous
melanoma cell line in vitro and in vivo.36 Moreover,ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Reciprocal signaling between CD133þ CSCs and their vascular
niches contributes to niche morphogenesis and CSC maintenance. Data
suggest that both the CSCs and the niche contribute to the niche
morphogenesis and homeostasis. For example, the CD133þ CSCs may
activate VM via VEGF- or b-cateninedependent mechanisms, leading to
deposition of LAMC2 in the niche microenvironment, which, in turn, en-
hances VM through a feedback loop. In addition, CD133þ CSC-derived VEGF
aids in tumor angiogenesis through endothelial cell (EC)-, EPC-, and CSC-
mediated mechanisms. Conversely, niche-associated extracellular matrix
galectin-3 can induce CD133 expression, and the VM phenotype (through
induction of CD144 and MMP2), in cancer cells. Depletion of galectin-3
results in the loss of the CD133þ subset and abolishes VM.
Targeting CD133 in Cancer Treatmentgalectin-3 is involved in promoting cell-surface expression
of the CD133 epitope, AC133, a marker speciﬁc to stem
cellelike states, in human embryonic kidney 293 cells
(Figure 3).9 These ﬁndings suggest that reciprocal in-
teractions between tumor cells and VM/niche-associated
ECM, such as galectin-3, may regulate CSC phenotype
and perivascular niche morphogenesis.
It is not entirely clear why CSCs reside in the perivascular
niche. In our perspective, this particular location allows
CSCs access to endothelial cells and endothelial stem and
progenitor cells (EPCs) to efﬁciently and conveniently
orchestrate complex microcirculatory networks to secure
nutrient supply; these networks are composed of authentic
blood vessels, through angiogenesis, and tumor-derived
circulatory networks, via transdifferentiation into CD31þ
tumor-derived endothelium (described in CD133 Subsets
Contribute to Angiogenesis of Endothelium-Lined Blood
Vessels via Dual Mechanisms) or CD31, CD144þ VM
channels. The proximity of the CSC niche to tumor vascu-
lature would also facilitate delivery of endocrine and envi-
ronmental cues involved in initiating and maintaining CSCs,
a hypothesis that would be consistent with the stochastic
model. In response to these external cues, CSCs undergoing
invasion to adjacent tissues or metastasis would have a less
structurally obstructed route, being in contact with the sys-
temic circulation.
Along with the blood-borne endocrine and environ-
mental cues, endothelial cells residing in brain tumorsThe American Journal of Pathology - ajp.amjpathol.orgsecrete certain factors in the perivascular niche to promote
brain CSC self-renewal and tumorigenesis.18 However,
whether VM channels secrete factors or provide direct cell
contact to maintain and protect CD133þ CSCs is presently
unknown. Given that we demonstrated that CD133þ
melanoma stem cells reside adjacent to authentic
endothelial-lined vessels, mosaic vessels, and VM chan-
nels (Figure 1), we hypothesize that multiple vascular
forms contribute to the perivascular niche in melanoma,
and that a continuum, or gradient, of vessel forms col-
laborates to establish the perivascular niche. Comparing
the contributions of varying vascular forms to the peri-
vascular niche will be an ongoing effort.
CD133 Subsets Contribute to Angiogenesis of
Endothelium-Lined Blood Vessels via Dual Mechanisms
Tumor vasculature provides an exchange of nutrients and
waste to support tumor growth and progression, as well as
laying a route for metastasesda signiﬁcant cause of cancer-
related morbidity and mortality. Various mechanisms
participate in tumor vascularization, including non-
sprouting and glomeruloid angiogenesis, postnatal vascu-
logenesis, intussusceptive microvascular growth, and the
previously mentioned VM.5,37 The varying forms of tumor
vasculature may be explained by plastic CSC and EPC
populations that can differentiate into endothelium or
endothelium-like structures. In fact, the CD133 fraction in
ovarian tumors is composed of the CSC subset and EPCs
that are capable of differentiating into vascular networks.38
For example, in response to environmental stresses, such
as nutrient starvation and hypoxia, hepatocellular carcinoma
cells can secrete pro-angiogenic factors, which actively re-
cruit CD133þ and VEGF receptor-2 (VEGFR-2)þ EPCs
from local pre-existing capillaries or from the bone marrow
to initiate tumor neovascularization.39,40
CD133þ EPCs are not always recruited from local pre-
existing capillaries or the bone marrow, but can also be
derived from neoplastic origins (Figure 1). Although
considered an endothelial protein in normal tissues,
VEGFR-2 is also preferentially expressed on CD133þ gli-
oma stem-like cells (Figure 3).41 Therefore, in addition to its
paracrine role in recruiting host EPCs, it is thought that
tumor-secreted VEGF can serve as an autocrine signal via
tumor-expressed VEGFR-2 (Figure 3). This is supported
with the report that VEGF is up-regulated in CD133þ me-
dulloblastoma cells compared with their CD133 counter-
parts.42 The importance of the VEGF/VEGFR-2/neuropilin
1 prosurvival signaling has been shown in endothelial
cells, which are required in tumor initiation and growth, as
well as maintaining CSC self-renewal in skin tumors.43
Moreover, CD133þ brain tumor stem cells can differen-
tiate into tumor EPCs that then participate in angiogenesis
by further differentiating into progeny resembling an
endothelial phenotype and expressing endothelial markers,
including CD31 (Figure 1).44e471259
Mak et alRecently, VEGF has been shown to be a direct physical
interaction partner of CD133. Speciﬁcally, soluble CD133
promotes the formation of VEGF165 dimers that are required
for binding to its VEGF receptors (Figure 3).15 These
ﬁndings support the notion that CD133 contributes to tumor
vascularization via a VEGF signaling mechanism
(Figure 1).15 Indeed, it has been demonstrated that targeting
CD133 in both primary human endothelial cells and in a
melanoma cell line results in aberrant and reduced tumor
microcirculation.15 Taken together, tumor angiogenesis may
be regulated through the interplay between VEGF, VEGF
receptors, and CD133-expressing EPCs, as well as tumor
cellederived EPCs.Targeting CSCs and the Vascular Niche via
CD133
In both the CSC hierarchical and stochastic models, tar-
geting existing CSCs and the induced new CSCs has been
proposed to be an effective strategy for cancer treatment.
Targeting CSCs can be achieved by direct approaches, or
possibly by impinging on the structure and function of their
vascular niche. The latter would particularly serve the sto-
chastic model because niche-dependent targeting strategies
may prevent the induction of dedifferentiation of cancer
cells into CSCs. Because recent studies have demonstrated
that CD133 is required for CSC identity, and for angio-
genesis15 and VM,12 which ultimately establishes the
vascular niche, we propose that targeting CD133 expression
or activity may disrupt the reciprocal signaling between the
CD133þ CSCs and their vascular niche, responsible for the
maintenance/induction of the CSC phenotype. Furthermore,
given the discussion of various tumor vascularization
mechanisms previously described, CD133 appears to serve a
role in deriving both normal and neoplastic endothelium, as
well as VM, suggesting that it contributes to vascular niche
morphogenesis regardless of the vessel type involved
(Figure 3). Thus, CD133 targeting bypasses the pitfall of
tumor plasticity by not only undertaking the pre-existing
CSCs but also preventing niche-dependent induction of
CSCs from the non-CSC populations through inhibition of
angiogenesis and VM.
Another niche-dependent approach includes targeting
EPC recruitment to tumor sites using anti-angiogenesis
therapies. Although traditionally the objective of this
approach would be to block the supply of oxygen and nu-
trients required for tumor survival and the route for metas-
tases, it would also serve to abolish the vascular niche and
disrupt residing CSCs. This would be a particularly attrac-
tive approach as the vascular niche maintains CSCs in a
quiescent and prosurvival state, which ultimately shields
them from anticancer therapies. Although targeting tumor
angiogenesis using the anti-VEGF monoclonal antibody
therapy has provided some promising preliminary ﬁndings
in xenograft mouse models harboring brain tumors,18 it has1260had minimal beneﬁts in patient survival rates.48,49 This
could be explained by the existence of tumors that have
either adapted or adopted VEGF-independent vasculariza-
tion mechanisms, VEGF resistance, and other redundant
pathways. We have focused herein on the hypothesis that
VEGF signaling may be involved in VM and trans-
differentiation of tumor cells into endothelium-like cells;
however, it is certainly possible that these vasculogenic
pathways may exist independently from VEGF. Further-
more, anti-angiogenesis treatments may encourage tumor
adoption of alternative vascularization mechanisms, such as
VM, that are resistant to anti-angiogenesis therapies,
resulting in increased tumor invasiveness and metastases.50
This makes it particularly important to consider combination
therapies that address both tumor cell (CSCs in particular)
and endothelium-derived vascularization mechanisms.
In support of targeting CD133, we have recently shown
that targeting the histone deacetylase 6 (HDAC6) expression
or its activity reduces CD133 stability and signaling,
resulting in reduced tumorigenesis, as well as increased
cancer cell death and differentiation in colon and ovarian
adenocarcinoma.30 More important, no physiological dif-
ferences were reported in an HDAC6 knockout mouse
model compared with wild-type mice,51 suggesting that
HDAC6 may be dispensable in normal cells, but not
cancerous ones. One concern of using drugs or molecules
that target CD133 in cancer stem and progenitor cells is the
result of retinal degeneration and vision loss as mouse
models and patients carrying certain CD133 gene mutations
acquire progressive retinal degeneration and blindness.4
However, it is possible that small-molecule inhibitors tar-
geting CD133 may be blocked from CD133þ retinal pro-
genitor cells because of the blood-ocular barrier, thus
preventing retinal degeneration and loss of vision.
On the basis of the current data, we propose that targeting
CD133 would be a novel and viable approach for cancer
treatment, in part by inhibiting various tumor vascularization
mechanisms and abolishing the CSCs simultaneously.
Although we, and others, have demonstrated that silencing
CD133 using RNA interference results in a signiﬁcant
reduction in tumor vascularization and size, further experi-
ments using anti-CD133 blocking antibodies or HDAC6
small-molecule inhibitors in xenograft mouse models are
warranted. These in vivo studies in mouse models are partic-
ularly important to investigate the impact of targeting CD133
in CD133þ normal stem and progenitor cell populations, such
as those in the retina, for potential adverse effects.Conclusions and Future Challenges
CD133þ CSCs are not randomly distributed but reside in a
complex vascular niche, encompassing authentic
endothelium-lined blood vessels, tumor-derived VM chan-
nels, and mosaic vessels, lined partially by VM-engaging
tumor cells, bona ﬁde vascular endothelial cells, or CSC-ajp.amjpathol.org - The American Journal of Pathology
Targeting CD133 in Cancer Treatmentderived endothelium. The formation of such an intricate
vascular niche is, at least in part, dependent on the CD133þ
subset within the tumor, which comprises not only the
CD133þ CSCs but also the CD133þ EPCs. For example,
CD133þ endothelial stem and progenitor cells (EPCs) can
be recruited for angiogenesis or vasculogenesis of the
tumor, and CD133þ CSCs have been shown to secrete pro-
angiogenic factors, as well as to differentiate into vascular
cells and VM channels. More importantly, reciprocal
signaling between CD133þ CSCs and niche-associated
ECM, endothelium, and their precursors (EPCs) is not
only pivotal in maintaining existing CSCs, but may induce
stem cell phenotype in the differentiated tumor populations.
Thus, therapeutic approaches aiming at CD133 targeting
may deliver multipronged effects by directly targeting the
CD133þ CSC population and disturbing their niches via
inhibition of diverse angiogenic forms as well as VM.
Regardless of the overwhelming evidence supporting an
essential role for CD133 in tumor vasculature and niche
morphogenesis, the underlying mechanisms that govern its
multifaceted function require further elucidation. For
example, despite sharing a role in the VEGF pathway, it is
unclear what signals control whether CD133þ CSCs
differentiate into CD31þ tumor endothelium or CD31 VM
channels. Furthermore, the mechanisms downstream of
CD133 in establishing the vascular niche and the gradient of
microenvironmental signals modulating the CSC phenotype
remain unknown. Through a therapeutic perspective, the
environmental cues that induce the conversion of CD133
cells to CD133þ CSCs require elucidation and may serve as
promising targets for novel niche-dependent therapeutic
strategies. As we continue to unveil the complexity of CSCs
and their surrounding niches, we are constantly reminded
that effective anticancer treatments will require strategic and
combined approaches to circumvent tumor plasticity and
heterogeneity. CD133-targeted therapy offers a promising
multipronged approach, bypassing the cancer stem cell
plasticity by disrupting the codependence between the CSCs
and their niches.
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